Table 3. Comparison of medications used between patients with and without CKD.
| VARIABLES | No CKD | eGFR < 60mL/min | Albuminúria (Alb) | eGFR < 60mL/min + Alb | p | ||||
|---|---|---|---|---|---|---|---|---|---|
| n = 242 | % | n = 11 | % | n = 12 | % | n = 9 | % | ||
| ACEI | 12 | 5.0% | 1 | 9.1% | 0 | 0,0% | 1 | 11.1% | 0.64 |
| ARA | 2 | 0.8% | 1 | 9.1% | 1 | 8.3% | 1 | 11.1% | < 0.01 |
| Efavirenz + Tenofovir + Emtricitabine | 84 | 34.7% | 1 | 9.1% | 3 | 25,0% | 2 | 22.2% | 0.26 |
| Tenofovir + Emtricitabine | 96 | 39.7% | 5 | 45.5% | 6 | 50,0% | 4 | 44.4% | 0.87 |
| Atazanavir + Ritonavir | 109 | 45.0% | 7 | 63.6% | 7 | 58.3% | 1 | 11.1% | 0.08 |
| Abacavir/Lamivudine | 50 | 20.7% | 4 | 36.4% | 3 | 25.0% | 4 | 44.4% | 0.23 |
| Lopinavir/Ritonavir | 20 | 8.3% | 1 | 9.1% | 0 | 0.0% | 1 | 11.1% | 0.75 |
| Saquinavir + Ritonavir | 8 | 3.3% | 1 | 9.1% | 1 | 8.3% | 2 | 22.2% | 0.03 |
| Zidovudina + Lamivudine | 3 | 1.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0.94 |
| Darunavir + Raltegravir + Ritonavir | 5 | 2.1% | 0 | 0.0% | 0 | 0.0% | 1 | 11.1% | 0.27 |
CKD: Chronic kidney disease; eGFR: Estimated glomerular rate by CKD-EPI; ACEI: Angiotensin-converting enzyme inhibitor; ARA: Angiotensin II receptor antagonist.